Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis

Company Overview

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Key Stats

• Today's Range: $0.07 to $0.08
• 50-Day Range: $0.07 to $0.10
• 52-Week Range: $0.04 to $0.16
• Volume: 163,384 shs
• Average Volume: 157,738 shs
• Market Capitalization: $31.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PVCT Stock Analysis - Frequently Asked Questions

How have PVCT shares performed this year?

Provectus Biopharmaceuticals' stock was trading at $0.1201 at the beginning of 2025. Since then, PVCT shares have decreased by 37.6% and is now trading at $0.0749.
View the best growth stocks for 2025 here.

How do I buy shares of Provectus Biopharmaceuticals?

Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Provectus Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), American Superconductor (AMSC), Cannabis Science (CBIS) and (DARA) (DARA).

Company Calendar

• Today: 6/20/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PVCT
• Previous Symbol: NYSEMKT:PVCT
• CIK: 315545
• Web: www.provectusbio.com
• Phone: (866) 594-5999
• Fax: 866-998-0005
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.76 million
• Net Margins: -815.81%
• Pretax Margin: -823.71%
• Return on Equity: N/A
• Return on Assets: -644.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.11
• Quick Ratio: 0.11

Sales & Book Value

• Annual Sales: $620 thousand
• Price / Sales: 50.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.01) per share
• Price / Book: -7.49

Miscellaneous

• Outstanding Shares: 420,280,000
• Free Float: 358,499,000
• Market Cap: $31.48 million
• Optionable: Not Optionable
• Beta: 0.78